Both CTLA and PD-1/PD-L1 inhibitors could strengthen the activation and proliferation of Teff cells, abrogate Treg cell function, induce inflammatory cytokines, probably boost humoral autoimmunity (88), and cause a range of autoimmunity-related adverse effects in multiple organs (Figure 2). This evidence concerns the gene PDCD1 and Autoimmunity.